Rxilient Receives Singapore Health Sciences Authority (HSA) Approval for Lumirix® Cream

We are pleased to share that Lumirix® Cream 15 mg/g has received approval from the Health Sciences Authority (HSA) of Singapore on 3 November 2026.

•      Product: Lumirix® Cream 15 mg/g 100g

•      Singapore Registration Number: SIN17673P

•      Approval Date: 3 November 2026

Lumirix® is the first treatment specifically approved in Singapore, for non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, representing an important advancement in the management of this chronic autoimmune disease.

Until now, vitiligo treatment options in Singapore have largely relied on off-label therapies such as topical corticosteroids, calcineurin inhibitors, and phototherapy. They have limited success in stopping the spread of vitiligo and encouraging repigmentation. In a prospective questionnaire study was conducted in a large cohort of vitiligo patients that consecutively visited the outpatient clinic of the Amsterdam University Medical Centre between April 2017 and January 2019, 49% reported that the current treatments were not effective and 50% was not satisfied with the current treatments.1,2 Existing topical treatments like potent topical corticosteroids also require regular monitoring by a doctor to prevent side effects.

The approval of Lumirix® helps address a longstanding unmet need by providing physicians with a targeted treatment option developed specifically for patients with non-segmental vitiligo.

References:

1.      Narayan V.S. Patients’perspective on current treatments and demand fornovel treatments in vitiligo. JEADV 2021, 35, 744–748

2.      Chan MF, Thng S. et al. Investigating factors associated with quality of life of vitiligo patients in Singapore, International Journal of Nursing Practice 2013; 19 (Suppl. 3), 3–10